PSIP1 and benign prostatic hyperplasia: Specific autoantibody signatures including TARDBP, TLN1, PARK7, LEDGF/PSIP1, and CALD1 and differentially reactive antigens (DIRAGs) also have been reported as biomarkers for distinguishing between PCa and BPH by the native antigen reverse capture microarray platform and the immunome of PCa [19, 20].